CN109789095A - 新的***片剂配方和组合物及其制造方法 - Google Patents

新的***片剂配方和组合物及其制造方法 Download PDF

Info

Publication number
CN109789095A
CN109789095A CN201780058464.XA CN201780058464A CN109789095A CN 109789095 A CN109789095 A CN 109789095A CN 201780058464 A CN201780058464 A CN 201780058464A CN 109789095 A CN109789095 A CN 109789095A
Authority
CN
China
Prior art keywords
powder
vegetable oil
ethyl alcohol
cannboid
hemp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780058464.XA
Other languages
English (en)
Chinese (zh)
Inventor
K·莱威
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenobi Growth Company
Original Assignee
Ebbu Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61017335&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109789095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ebbu Co filed Critical Ebbu Co
Publication of CN109789095A publication Critical patent/CN109789095A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201780058464.XA 2016-07-25 2017-07-25 新的***片剂配方和组合物及其制造方法 Pending CN109789095A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662366517P 2016-07-25 2016-07-25
US62/366,517 2016-07-25
PCT/US2017/043808 WO2018022669A1 (en) 2016-07-25 2017-07-25 New cannabis tablet formulations and compositions and methods of making the same

Publications (1)

Publication Number Publication Date
CN109789095A true CN109789095A (zh) 2019-05-21

Family

ID=61017335

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780058464.XA Pending CN109789095A (zh) 2016-07-25 2017-07-25 新的***片剂配方和组合物及其制造方法

Country Status (12)

Country Link
US (3) US20190183850A1 (es)
EP (1) EP3487482A4 (es)
CN (1) CN109789095A (es)
AU (1) AU2017302559A1 (es)
BR (1) BR112019001528A8 (es)
CA (1) CA3031533A1 (es)
CL (1) CL2019000198A1 (es)
CO (1) CO2019000787A2 (es)
IL (1) IL264386B2 (es)
MX (1) MX2019001121A (es)
PE (1) PE20200478A1 (es)
WO (1) WO2018022669A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114845705A (zh) * 2020-01-08 2022-08-02 雀巢产品有限公司 用于治疗胃肠疾病的口服固体***素油组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092060A1 (en) * 2018-02-23 2019-08-29 Columbia Care Llc Hard-pressed scored splittable marijuana tablets
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
US20210393573A1 (en) * 2018-10-30 2021-12-23 Kelsie Biotech, Llc Tablets, formulations and methods for low melting point active ingredients
US20220023220A1 (en) * 2019-01-10 2022-01-27 Columbia Care Llc Rapidly disintegrating oral tablet
US11633351B2 (en) 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
CA3040547C (en) 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
WO2022243936A1 (en) * 2021-05-21 2022-11-24 Swm Luxembourg Process for incorporating additives into aerosol-producing substrates and products made therefrom

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016882A1 (en) * 1990-05-08 1991-11-14 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
WO2002064109A2 (en) * 2001-02-14 2002-08-22 Gw Pharma Limited Mucoadhesive pharmaceutical formulations
US7553500B2 (en) * 2002-07-10 2009-06-30 Pfizer Inc Pharmaceutical composition having uniform drug distribution and potency
US20100034888A1 (en) * 2006-09-15 2010-02-11 Hubert Clemens Pellikaan Granulate containing a pharmaceutically active substance and method for its manufacture
EP2570121A1 (en) * 2010-05-10 2013-03-20 Xie, Tian Slow release tablet of elemene anti-tumor plant medicine
US20160015683A1 (en) * 2014-07-21 2016-01-21 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
WO2016084075A1 (en) * 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US20160166498A1 (en) * 2014-12-16 2016-06-16 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016882A1 (en) * 1990-05-08 1991-11-14 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US5976574A (en) * 1996-12-31 1999-11-02 Inhale Therapeutic Systems Processes for spray drying hydrophobic drugs in organic solvent suspensions
WO2002064109A2 (en) * 2001-02-14 2002-08-22 Gw Pharma Limited Mucoadhesive pharmaceutical formulations
US7553500B2 (en) * 2002-07-10 2009-06-30 Pfizer Inc Pharmaceutical composition having uniform drug distribution and potency
US20100034888A1 (en) * 2006-09-15 2010-02-11 Hubert Clemens Pellikaan Granulate containing a pharmaceutically active substance and method for its manufacture
EP2570121A1 (en) * 2010-05-10 2013-03-20 Xie, Tian Slow release tablet of elemene anti-tumor plant medicine
US20160015683A1 (en) * 2014-07-21 2016-01-21 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
WO2016084075A1 (en) * 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US20160166498A1 (en) * 2014-12-16 2016-06-16 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114845705A (zh) * 2020-01-08 2022-08-02 雀巢产品有限公司 用于治疗胃肠疾病的口服固体***素油组合物

Also Published As

Publication number Publication date
CO2019000787A2 (es) 2019-04-30
US20190183850A1 (en) 2019-06-20
US20220323403A1 (en) 2022-10-13
AU2017302559A1 (en) 2019-02-07
EP3487482A1 (en) 2019-05-29
EP3487482A4 (en) 2020-03-04
WO2018022669A1 (en) 2018-02-01
BR112019001528A2 (pt) 2019-06-18
CL2019000198A1 (es) 2019-05-31
IL264386A (en) 2019-02-28
PE20200478A1 (es) 2020-03-03
IL264386B2 (en) 2023-08-01
IL264386B1 (en) 2023-04-01
BR112019001528A8 (pt) 2019-07-09
US20210100771A1 (en) 2021-04-08
CA3031533A1 (en) 2018-02-01
MX2019001121A (es) 2019-10-21

Similar Documents

Publication Publication Date Title
CN109789095A (zh) 新的***片剂配方和组合物及其制造方法
CN110177543A (zh) 包含纯化***素的水溶性组合物
US10821147B2 (en) Printable cannabinoid and terpene compositions
US20200170950A1 (en) Compositions comprising a cannabinoid or a cannabis-derived compound, methods of making and use
JP7436209B2 (ja) 活性成分を有する乾燥フレーク
CA3031123C (en) Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
EP3589129A1 (en) Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
US20210038666A1 (en) Printable cannabinoid and terpene compositions
US11346051B2 (en) Aromatized and flavored paper products
WO2023028708A1 (en) Water-soluble cannabinoid compositions, methods of making and use
CN110382777A (zh) 具有香气及味道的纸制品
WO2020044343A1 (en) Aromatized and flavored paper products comprising terpenes and cannabinoids
Velikorodov et al. The Chemical Composition of Essential Oils from Wildgrowing and Introduced Plants of the Astrakhan Region
WO2019171170A1 (en) Device and method for administering an active ingredient
US20230285485A1 (en) Optimizing volatile entourages in dry flowering plant mixtures

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right

Effective date of registration: 20190515

Address after: Ontario, Canada

Applicant after: Kenobi Growth Company

Address before: American Colorado

Applicant before: EBBU company

TA01 Transfer of patent application right
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190521

WD01 Invention patent application deemed withdrawn after publication